From these data, they postulated that navitoclax may be an attractive therapeutic drug candidate for human oral cancer therapy with CHOP as its alternative target in regulating the apoptotic activity and the side effects are also minimal. The gene discussed is DDIT3; the disease is lip and oral cavity carcinoma.